Clinical evidence for osteoarthritis as an inflammatory disease

Current Rheumatology Reports

Volumn 3, Issue 6, 2001, Pages 524-534

  Pincus, Theodore ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetaminophen; Etodolac; Misoprostol; Nabu; Nabumetone

Indexed keywords

ARTHROTEC; DICLOFENAC; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; DRUG COMBINATION; HUMAN; INFLAMMATION; MIDDLE AGED; OSTEOARTHRITIS; PATHOLOGY; REVIEW; RISK FACTOR; SOCIOECONOMICS;

ACETAMINOPHEN; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG COMBINATIONS; HUMANS; INFLAMMATION; MIDDLE AGED; MISOPROSTOL; OSTEOARTHRITIS; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 0035653634     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-001-0068-4     Document Type: Article

References (52)

1. Huskisson EC, Dieppe PA, Tucker AK, Cannell LB: Another look at osteoarthritis. Ann Rheum Dis 1979, 38:423–428.
2. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease - potential implication for the selection of new therapeutic targets. Review. Arthritis Rheum 2001, 44:1237–1247. An outstanding review documenting evidence for chondrocytes as a source of matrix metalloproteinase, proinflammatory cytokines, including TNFa and IL-1b, nitric oxide, and prostaglandins in osteoarthritis. The implication for new therapeutic approaches is elegantly discussed. DOI: 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F
3. van de Loo FAJ, Joosten LAB, van Lent PLEM, et al.: Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164–172. DOI: 10.1002/art.1780380204
4. Caron JP, Fernandes JC, Martel-Pelletier J, et al.: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535–1544. DOI: 10.1002/art.1780390914
5. Hirsch R, Lethbridge-Cejku M, Scott WW, et al.: Association of hand and knee osteoarthritis: Evidence for a polyarticular disease subset. Ann Rheum Dis 1996, 55:25–29. DOI: 10.1136/ard.55.1.25
6. Hochberg MC, Lane NE, Pressman AR, et al.: The association of radiographic changes of osteoarthritis of the hand and hip in elderly women. J Rheumatol 1995, 22:2291–2294.
7. Hart DJ, Doyle DV, Spector TD: Association between metabolic factors and knee osteoarthritis in women: The Chingford study. J Rheumatol 1995, 22:1118–1123.
8. Anderson JJ, Felson DT: Factors associated with osteoarthritis of the knee in the first national health and nutrition examination survey (HANES I): evidence for an association with overweight, race and physical demands of work. Am J Epidemiol 1988, 128:179–189.
9. Davis MA, Ettinger WH, Neuhaus JM: The role of metabolic factors and blood pressure in the association of obesity with osteoarthritis of the knee. J Rheumatol 1988, 15:1827–1832.
10. Martin K, Lethbridge-Cejku M, Muller DC, et al.: Metabolic correlates of obesity and radiographic features of knee osteoarthritis: Data from the Baltimore longitudinal study of aging. J Rheumatol 1997, 24:702–707.
11. Cooper C, McAlindon T, Snow S, et al.: Mechanical and constitutional risk factors of symptomatic knee osteoarthritis: Difference between medial tibiofemoral and patellofemoral disease. J Rheumatol 1994, 21:307–313.
12. McAlindon T, Zhang Y, Hannan M, et al.: Are risk factors for patellofemoral and tibiofemoral knee osteoarthritis different? J Rheumatol 1996, 23:332–337.
13. Antonovsky A: Social class and the major cardiovascular diseases. J Chronic Dis 1968, 21:65–106. DOI: 10.1016/0021-9681(68)90098-2
14. Kitagawa EM, Hauser PM: Differential Mortality in the United States: A Study in Socioeconomic Epidemiology. Cambridge: Harvard University Press; 1973.
15. Marmot MG, Kogevinas M, Elston MA: Social/economic status and disease. Annu Rev Public Health 1987, 8:111–135. DOI: 10.1146/annurev.pu.08.050187.000551
16. Sagan LA: The health of nations: true causes of sickness and well-being. New York: Basic Books; 1987.
17. Weinblatt E, Ruberman W, Goldberg JD, et al.: Relation of education to sudden death after myocardial infarction. N Engl J Med 1978, 299:60–65. DOI: 10.1056/NEJM197807132990202
18. Adler NE, Boyce WT, Chesney MA, et al.: Socioeconomic inequalities in health: No easy solution. JAMA 1993, 269:3140–3145. DOI: 10.1001/jama.269.24.3140
19. Pincus T: Formal educational level—a marker for the importance of behavioral variables in the pathogenesis, morbidity, and mortality of most diseases? Editorial. J Rheumatol 1988, 15:1457–1460.
20. Pincus T, Callahan LF: Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic Dis 1985, 38:973–984. DOI: 10.1016/0021-9681(85)90095-5
21. Pincus T, Callahan LF, Burkhauser RV: Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18–64 United States population. J Chronic Dis 1987, 40:865–874. DOI: 10.1016/0021-9681(87)90186-X
22. Pincus T, Callahan LF: What explains the association between socioeconomic status and health: Primarily medical access or mind-body variables? Advances 1995, 11:4–36.
23. Pincus T, Esther R, DeWalt DA, Callahan LF: Social conditions and self-management are more powerful determinants of health than access to care. Ann Intern Med 1998, 129:406–411.
24. Hannan MT, Anderson JJ, Pincus T, Felson DT. Educational attainment and osteoarthritis: Differential associations with radiographic changes and symptom reporting. J Clin Epidemiol 1992, 45:139–147. DOI: 10.1016/0895-4356(92)90006-9
25. Pincus T, Mitchell JM, Burkhauser RV: Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: Comparisons with rheumatoid arthritis. J Clin Epidemiol 1989, 42:449–457. DOI: 10.1016/0895-4356(89)90135-2
26. Mitchell JM, Burkhauser RV, Pincus T: The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988, 31:348–357. DOI: 10.1002/art.1780310306
27. Pincus T, Callahan LF: Associations of low formal education level and poor health status: Behavioral, in addition to demographic and medical, explanantions? J Clin Epidemiol 1994, 47:355–361. DOI: 10.1016/0895-4356(94)90156-2
28. Callahan LF, Smith WJ, Pincus T: Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989, 2:122–131. DOI: 10.1002/anr.1790020406
29. Hochberg MC, Altman RD, Brandt KD, et al.: Guidelines for the medical management of osteoarthritis, I: Osteoarthritis of the hip. Arthritis Rheum 1995, 38:1535–1540. DOI: 10.1002/art.1780381103
30. MC, Altman RD, Brandt KD, et al.: Guidelines for medical management of osteoarthritis, II: Osteoarthritis of the knee. Arthritis Rheum 1995, 38:1541–1546. DOI: 10.1002/art.1780381104
31. American College of Rheumatology: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000, 43:1905–1915. Updated recommendations of the American College of Rheumatology Subcommittee on guidelines for the treatment of osteoarthritis are of importance to all physicians. DOI: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P
32. Griffin MR, Ray WA, Schaffner W: Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988, 109:359–363.
33. Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991, 91:213–222. DOI: 10.1016/0002-9343(91)90118-H
34. Fries JF, Miller SR, Spitz PW, et al.: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989, 96:647–655.
35. Fries JF, Miller SR, Spitz PW, et al.: Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990, 17:12–19.
36. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 115:787–796.
37. Wolfe MM, Lichenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–1899. An updated review concerning the gastrointestinal toxicity of traditional nonsteroidal anti-inflammatory drugs. DOI: 10.1056/NEJM199906173402407
38. Griffin MR, Brandt KD, Liang MH, et al.: Practical management of osteoarthritis: Integration of pharmacologic and nonpharmacologic measures. Arch Fam Med 1995, 4:1049–1055. DOI: 10.1001/archfami.4.12.1049
39. Rodriguez LAG, Hernandez-Diaz S: The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Research 2001, 3:98–101. An analysis of the United Kingdom General Practice Survey, which indicates that users of acetaminophen at doses of 2 g/day appear to have risks of gastrointestinal complications similar to those associated with nonsteroidal anti-inflammatory drugs. DOI: 10.1186/ar146
40. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87–91. DOI: 10.1056/NEJM199107113250203
41. Williams HJ, Ward JR, Egger MJ, et al.: Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993, 363:1196–1206. DOI: 10.1002/art.1780360904
42. Pincus T, Swearingen C, Cummins P, Callahan LF: Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000, 27:1020–1027. One of two clinical surveys that documents a strong preference for nonsteroidal anti-inflammatory drugs rather than acetaminophen in 300 patients with osteoarthritis who were asked about their ratings of drugs used over long periods.
43. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. Arthritis Rheum 2000, 43:378–385. Another survey of ratings of drugs by 668 patients with osteoarthritis indicating a strong preference for nonsteroidal anti-inflammatory drugs versus acetaminophen. DOI: 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2
44. Pincus T, Koch GG, Sokka T, et al.: A randomized, doubleblind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587–1598. A randomized, double-blind crossover clinical trial that indicates that diclofenac + misoprostol had greater efficacy than acetaminophen in most patients. Patients with milder disease tended to have greater similarity of efficacy with diclofenac + misoprostol versus acetaminophen. Tolerability and toxicity were greater with diclofenac + misoprostol, but were not inconsequential with acetaminophen. DOI: 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X
45. Ameer, B, DJ: Acetaminophen. Ann Intern Med 1977, 87:202–209.
46. Towheed TE, Hochberg MC: A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997, 26:755–770. DOI: 10.1016/S0049-0172(97)80043-1
47. Jayson MIV: Chronic back pain is not the same as acute back pain lasting longer. BMJ 1997, 314:1639–1640.
48. Felson DT: Editorial: The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis Rheum 2001, 44:1477–1480. A summary of three clinical trials that compare nonsteroidal antiinflammatory drugs (NSAIDs) to acetaminophen. The effect-sizes of advantages to NSAIDs versus acetaminophen are similar in the three trials, although differences were not statistically significant in two, possibly because of insufficient numbers of patients. DOI: 10.1002/1529-0131(200107)44:7<1477::AID-ART267>3.0.CO;2-O
49. Pincus T: Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993, 23:2–10. DOI: 10.1016/S0049-0172(10)80002-2
50. Pincus T, Stein CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997, 15:S27-S38.
51. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999, 282:1921–1928. DOI: 10.1001/jama.282.20.1921
52. Cannon GW, Caldwell JR, Holt P, et al.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000, 43:978–987. DOI: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0